First entirely AI developed drug green lit for clinical trial

By Staff Reporter

- Last updated on GMT

(Image: Getty/Metamorworks)
(Image: Getty/Metamorworks)

Related tags: Exscientia, AI, Drug discovery, Sumitomo Dainippon Pharma

A drug candidate for obsessive-compulsive disorder will enter clinical trials, after being discovered and readied in under 12 months.

This rapid turnaround from discovery to clinical trial is part of the reason that industry is excited about the potential for artificial intelligence​. Usually, the drug development pathway averages four and a half years to get to the same stage, noted one of the companies involved, Exscientia.

The drug is DSP-1181, which is a long-acting and potent serotonin 5-HT1A​ receptor agonist, which will enter Phase I trials in Japan for obsessive-compulsive disorder.

The drug candidate was created through the joint research of Japanese pharma company Sumitomo Dainippon Pharma and Exscientia, with the latter providing the Centaur Chemist AI platform for discovery.

Andrew Hopkins, CEO of Exscientia, stated: "We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery.”

While the company’s Twitter account​ suggested that it expects all drugs by the end of the decade to be developed using AI.

Several pharma companies have expressed their own confidence in this prospect, with both Sanofi​ and, more recently, Bayer​ entering multi-million drug development deals with the AI specialist.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars